CCL20, a direct-acting pro-angiogenic chemokine induced by hepatitis C virus (HCV): Potential role in HCV-related liver cancer

被引:52
作者
Benkheil, Mohammed [1 ]
Van Haele, Matthias [2 ]
Roskams, Tania [2 ]
Laporte, Manon [1 ]
Noppen, Sam [1 ]
Abbasi, Kayvan [1 ]
Delang, Leen [1 ]
Neyts, Johan [1 ]
Liekens, Sandra [1 ]
机构
[1] Univ Leuven KU Leuven, Rega Inst Med Res, Lab Virol & Chemotherapy, Leuven, Belgium
[2] Univ Leuven KU Leuven, Dept Imaging & Pathol, Translat Cell & Tissue Res, Leuven, Belgium
关键词
Chemokine; Angiogenesis; Hepatocellular carcinoma; Hepatitis C virus; LIGAND; 20; EXPRESSION; INFECTION; RECEPTOR; CELLS; ACTIVATION; PATHWAYS;
D O I
10.1016/j.yexcr.2018.09.023
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The CCL20/CCR6 chemokine/receptor axis has previously been shown to contribute to the initiation and progression of hepatocellular carcinoma (HCC) through the recruitment of CCR6-positive leukocytes to the tumor microenvironment. In particular, high serum levels of CCL20 are reported in patients with HCC induced by the hepatitis C virus (HCV). A potential non-immune role for the CCL20/CCR6 axis in HCC development has not yet been investigated. Microarray analysis (Benkheil et al., paper submitted for publication), revealed that CCL20 is highly upregulated in hepatoma cells infected with HCV compared with non-infected hepatoma cells. To determine the role of the CCL20/CCR6 axis in HCV-related HCC, we first explored which cell populations express CCR6 in human liver tissue with chronic disease or HCC. Immunohistochemical (IHC) analysis revealed that CCR6 is present on endothelial cells (ECs) of portal blood vessels in livers with chronic HCV infection and in HCV- and alcoholic-HCC tissue. In addition, we found CCR6 to be expressed on primary macrovascular (HUVECs) and microvascular ECs (HMVEC-ds) where it co-expressed with the endothelial marker CD31. In vitro angiogenesis experiments revealed that CCL20 is a direct pro-angiogenic molecule that induces EC invasion, sprouting and migration through CCR6. Moreover, using the angiogenesis matrigel plug assay in immunodeficient NMRI-nu mice, we clearly showed that CCL20 induces blood vessel formation, by attracting CCR6-positive ECs. Finally, we demonstrated that HCV-induced CCL20 protein expression and secretion in hepatoma cells could be abolished by antiviral treatment, indicating that CCL20 expression is dependent on HCV replication. In contrast to HCV, HBV-infection resulted in a decreased expression of CCL20, implying a virus-specific effect. Taken together, we identified HCV-induced CCL20 as a direct pro-angiogenic factor that acts on endothelial CCR6. These results suggest that the CCL20/CCR6 axis contributes to hepatic angiogenesis, promoting the hypervascular state of HCV-HCC.
引用
收藏
页码:168 / 177
页数:10
相关论文
共 48 条
  • [31] Long-Term Risk of Hepatocellular Carcinoma Following Direct-Acting Antiviral Therapy in Compensated Liver Cirrhosis Induced by Hepatitis C Virus Infection
    Muzica, Cristina Maria
    Stanciu, Carol
    Cijevschi-Prelipcean, Cristina
    Girleanu, Irina
    Huiban, Laura
    Petrea, Oana Cristina
    Singeap, Ana-Maria
    Cojocariu, Camelia
    Cuciureanu, Tudor
    Sfarti, Catalin
    Zenovia, Sebastian
    Chriac, Stefan
    Stefanescu, Gabriela
    Ciortescu, Irina
    Lupascu-Ursulescu, Corina
    Miftode, Egidia
    Trifan, Anca
    [J]. HEPATITIS MONTHLY, 2021, 21 (06)
  • [32] Mitochondrial DNA copy number in Hepatitis C virus-related chronic liver disease: impact of direct-acting antiviral therapy
    Elyamany, Amany
    Ghazala, Rasha
    Fayed, Omnia
    Hamed, Yasmin
    El-Shendidi, Assem
    [J]. SCIENTIFIC REPORTS, 2023, 13 (01)
  • [33] Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation
    Anthony, Donald D.
    Sulkowski, Mark S.
    Smeaton, Laura M.
    Damjanovska, Sofi
    Shive, Carey L.
    Kowal, Corinne M.
    Cohen, Daniel E.
    Bhattacharya, Debika
    Alston-Smith, Beverly L.
    Balagopal, Ashwin
    Wyles, David L.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2020, 222 (08) : 1334 - 1344
  • [34] Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver Disease
    Ogata, Fumihiro
    Kobayashi, Masahiro
    Akuta, Norio
    Osawa, Mitutaka
    Fujiyama, Shunichiro
    Kawamura, Yusuke
    Sezaki, Hitomi
    Hosaka, Tetsuya
    Kobayashi, Mariko
    Saitoh, Satoshi
    Suzuki, Yoshiyuki
    Suzuki, Fumitaka
    Arase, Yasuji
    Ikeda, Kenji
    Kumada, Hiromitsu
    [J]. ONCOLOGY, 2017, 93 (02) : 92 - 98
  • [35] Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity—LINA cohort)
    Ivan Gentile
    Riccardo Scotto
    Carmine Coppola
    Laura Staiano
    Daniela Caterina Amoruso
    Teresa De Simone
    Federica Portunato
    Stefania De Pascalis
    Salvatore Martini
    Margherita Macera
    Giulio Viceconte
    Grazia Tosone
    Antonio Riccardo Buonomo
    Guglielmo Borgia
    Nicola Coppola
    [J]. Hepatology International, 2019, 13 : 66 - 74
  • [36] Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study
    Ferrarese, Alberto
    Germani, Giacomo
    Gambato, Martina
    Russo, Francesco Paolo
    Senzolo, Marco
    Zanetto, Alberto
    Shalaby, Sarah
    Cillo, Umberto
    Zanus, Giacomo
    Angeli, Paolo
    Burra, Patrizia
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2018, 24 (38) : 4403 - 4411
  • [37] Risk factors for liver-related mortality of patients with hepatitis C virus after sustained virologic response to direct-acting antiviral agents
    Hattori, Nobuhiro
    Ikeda, Hiroki
    Watanabe, Tsunamasa
    Satta, Yosuke
    Ehira, Takuya
    Suzuki, Tatsuya
    Kiyokawa, Hirofumi
    Nakahara, Kazunari
    Takahashi, Hideaki
    Matsunaga, Kotaro
    Matsumoto, Nobuyuki
    Yasuda, Hiroshi
    Suzuki, Michihiro
    Itoh, Fumio
    Tateishi, Keisuke
    [J]. JGH OPEN, 2022, 6 (10): : 685 - 691
  • [38] Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients
    Li, Zhanyi
    Liu, Ying
    Zhang, Ying
    Shao, Xiaoqiong
    Luo, Qiumin
    Guo, Xiaoyan
    Lin, Guoli
    Cai, Qingxian
    Zhao, Zhixin
    Chong, Yutian
    [J]. BIOMED RESEARCH INTERNATIONAL, 2017, 2017
  • [39] Serum inducible protein 10 kDa/C-X-C motif chemokine 10 levels predict regression of M2BPGi-based liver fibrosis after hepatitis C virus eradication by direct-acting antiviral agentss
    Nagura, Yoshihito
    Suzuki, Takanori
    Matsuura, Kentaro
    Ogawa, Shintaro
    Kawamura, Hayato
    Kuno, Kayoko
    Fujiwara, Kei
    Nojiri, Shunsuke
    Nagaoka, Katsuya
    Iio, Etsuko
    Watanabe, Takehisa
    Kataoka, Hiromi
    Tanaka, Yasuhito
    [J]. HEPATOLOGY RESEARCH, 2024, 54 (01) : 32 - 42
  • [40] Liver Angiopoietin-2 Is a Key Predictor of De Novo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct-Acting Antivirals
    Faillaci, Francesca
    Marzi, Luca
    Critelli, Rosina
    Milosa, Fabiola
    Schepis, Filippo
    Turola, Elena
    Andreani, Silvia
    Vandelli, Gabriele
    Bernabucci, Veronica
    Lei, Barbara
    D'Ambrosio, Federica
    Bristot, Laura
    Cavalletto, Luisa
    Chemello, Liliana
    Sighinolfi, Pamela
    Manni, Paola
    Maiorana, Antonino
    Caporali, Cristian
    Bianchini, Marcello
    Marsico, Maria
    Turco, Laura
    de Maria, Nicola
    Del Buono, Mariagrazia
    Todesca, Paola
    di Lena, Luca
    Romagnoli, Dante
    Magistri, Paolo
    di Benedetto, Fabrizio
    Bruno, Savino
    Taliani, Gloria
    Giannelli, Gianluigi
    Martinez-Chantar, Maria-Luz
    Villa, Erica
    [J]. HEPATOLOGY, 2018, 68 (03) : 1010 - 1024